TOKYO, July 17, 2019 - (JCN Newswire) - Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane
, from the China National Medical Products Administration (NMPA).
Patients should have been previously treated with an anthracycline and/or a taxane
in the adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments.
Food and Drug Administration (FDA) has approved Kadcyla[R] (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant (before surgery) taxane
and Herceptin[R] (trastuzumab)-based treatment.
The approval is for adjuvant, or after surgery, treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant, or before surgery, taxane
and Herceptin (trastuzumab)-based treatment.
Furthermore, HRQoL tended to decrease during treatment with either taxane
. Better management of taxane-related adverse events is therefore required.
for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease, including an anthracycline and a taxane
in either the adjuvant or metastatic setting.
Methods: We included 30 patients who received at least 6 cycles of taxane
regimen for metastatic mPC in the present study.
An analysis based on type of therapy showed that 65.1% of those receiving a taxane
experienced hair preservation, compared with 21.9% of those receiving an anthracycline.
TAXYNERGY trial shows that early taxane
switch may improve PSA response rate and that androgen receptor nuclear localization may indicate taxane
It is an orally available tubulin targeting agent that has demonstrated efficacy in preclinical studies against hormone sensitive, castration resistant, as well as taxane
resistant prostate cancer.
Results: Oral administration of taxane
fractions isolated from Taxus chinensis (containing 17.2% PTX) could achieve remarkably higher blood concentration and systemic exposure of PTX in rats, while the retention of PTX was significantly improved.
Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin (trastuzumab) and a taxane
, separately or in combination.